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Abstract G protein-coupled receptor kinases (GRKs) phos-
phorylate G protein-coupled receptors, thereby terminating
receptor signaling. Herein we report that K-actinin potently
inhibits all GRK family members. In addition, calcium-bound
calmodulin and phosphatidylinositol 4,5-bisphosphate (PIP2),
two regulators of GRK activity, coordinate with K-actinin to
modulate substrate specificity of the GRKs. In the presence of
calmodulin and K-actinin, GRK5 phosphorylates soluble, but not
membrane-incorporated substrates. In contrast, in the presence
of PIP2 and K-actinin, GRK5 phosphorylates membrane-
incorporated, but not soluble substrates. Thus, modulation of
K-actinin-mediated inhibition of GRKs by PIP2 and calmodulin
has profound effects on both GRK activity and substrate
specificity.
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1. Introduction
The rapid response of most G protein-coupled receptors
(GPCRs) to an agonist is closely followed by the recruitment
of G protein-coupled receptor kinases (GRKs). GRKs are
divided into three subfamilies based on sequence and func-
tional similarities : GRK1 (rhodopsin kinase), GRK2 and 3
(L-adrenergic receptor kinases 1 and 2) and GRK4, 5 and 6.
The GRK family is well characterized for its ability to phos-
phorylate GPCR and terminate traditional signaling cascades
by homologous desensitization. GRK phosphorylation of
most GPCRs recruits an arrestin family member which binds
the GPCR and initiates its internalization [1].
Additional recently elucidated roles for GRKs demonstrate
that these kinases are not simply terminators of signaling, but
also can initiate signal transduction. GPCRs can activate the
mitogen-activated protein kinase pathway through a G pro-
tein LQ-dependent activation of Ras [2]. Additionally, Premont
et al. [3], recently identi¢ed a GRK interacting protein (GIT1)
with ADP-ribosylation factor-GTPase activation protein
(ARF-GAP) activity. Overexpression of GIT1 has profound
e¡ects on the signaling mediated through a prototypical
GPCR, the L2-adrenergic receptor (L2AR). The cellular e¡ects
of GIT1 are dependent on the ARF-GAP domain of this
protein, therefore suggesting that GRKs may serve to inte-
grate signals from GPCRs to the small GTPase ARF. The
¢nding that GRK2 is a tubulin kinase [4^6] further suggests
roles for GRKs beyond simply terminating GPCR signaling.
The identi¢cation of tubulin as a non-receptor, soluble sub-
strate of GRK2 also suggests that there may be additional
unidenti¢ed substrates for each of the GRKs.
The potential pleiotropic roles of the GRKs suggest that it
is necessary that kinase activity be tightly regulated. GRK-
mediated phosphorylation is known to be regulated by phos-
phatidylinositol 4,5-bisphosphate (PIP2), calmodulin and ac-
tin. PIP2 enhances GRK-mediated phosphorylation of
GPCRs by co-localizing kinase and substrate [1]. Conversely,
calmodulin interferes with GRK translocation to membranes
[7], thereby inhibiting GRK-mediated phosphorylation of
GPCRs without a¡ecting the phosphorylation of soluble sub-
strates such as casein. Recently, we characterized actin as a
novel inhibitor of GRK5 function. In contrast to PIP2 and
calmodulin, which modulate only membrane localization and
thus GPCR phosphorylation, actin directly inhibits GRK-
mediated phosphorylation of both soluble and membrane-in-
corporated substrates [8].
During our characterization of the actin-mediated inhibi-
tion of GRK5, we discovered another inhibitor of GRK5,
the actin binding protein K-actinin. K-Actinin is a member
of the spectrin superfamily of actin crosslinking proteins.
Both spectrin and K-actinin are found in most cell types.
K-Actinin is most abundant in muscle cells, while spectrin
(also known as fodrin) is a major component of erythrocyte
membranes and comprises 3% of the total particulate protein
in brain tissue [9]. In addition to binding and crosslinking
actin, K-actinin and spectrin also bind lipid, thus creating a
submembraneous meshwork of crosslinked actin. Spectrin and
K-actinin also bind various ion channels, cell adhesion mole-
cules and transmembrane receptors and incorporate them into
this actin network to create specialized signaling domains [9].
Here, we demonstrate that K-actinin is a potent inhibitor of
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all members of the GRK family and identify a regulatory
mechanism whereby K-actinin modulates both the activity
and substrate speci¢city of these enzymes.
2. Materials and methods
2.1. Materials
Bovine milk L-casein and phosphatidyl serine (PS) (Sigma); bovine
brain calmodulin (Calbiochem); PIP2 (Boehringer Mannheim) and
protein kinase A (PKA) (Promega) were purchased for these studies.
GRK1, GRK2 and GRK5 were puri¢ed from Sf9 insect cells as pre-
viously described [10^12]. Chicken gizzard (smooth muscle) K-actinin
was either purchased from Sigma or puri¢ed as previously described
[13]. Similar results were obtained when using both preparations.
Spectrin was puri¢ed as previously described and dialyzed into
10 mM phosphate bu¡er, pH 7.4, 50 mM NaBr, 1 mM NaN3,
0.05% Tween and 1 mM DTT [14]. Pro¢lin was a generous gift
from Don Kaiser and Tom Pollard. Puri¢ed peptide (RRREEEEE-
SAAA) was prepared in Tris, adjusting the pH to 7.2. Rod outer
segment membranes containing rhodopsin were puri¢ed as previously
described [15]. L2AR was puri¢ed and reconstituted in either 5% PIP2/
95% PS or 100% PS as previously described [16,17].
2.2. Phosphorylation of protein substrates
GRK or PKA, normalized for equivalent casein kinase activity, and
the indicated concentration of actin binding proteins were incubated
with either rod outer segments containing rhodopsin, L2AR (3 pmol)
or casein (20 Wg) at 30‡C for 5, 10 or 15 min respectively, in 20 mM
Tris, pH 7.5, 10 mM MgCl2, 2 mM EDTA, 1 mM DTT and 60 WM
ATP (1 WCi). Reactions examining the e¡ect of calmodulin contained
2 mM CaCl2, which in itself does not alter kinase activity. For GPCR
or casein phosphorylation, 25 Wl of sample loading bu¡er (100 mM
Tris, pH 7.2, 4% SDS, 200 mM DTT, 0.25% pyronin Y, 20% glycerol)
was added to terminate the 25 Wl reaction and the samples were sub-
jected to sodium dodecyl sulfate^polyacrylamide gel electrophoresis.
The gels were dried and exposed to a PhosphorImager screen (Mo-
lecular Dynamics). The amount of phosphorylation was quantitated
using Image Quant and the mean of at least three independent experi-
ments is expressed as a percent of substrate phosphorylation in the
absence of any added inhibitors.
2.3. GRK5-mediated phosphorylation of a soluble synthetic peptide
substrate
GRK5-mediated phosphorylation of peptide substrate was deter-
mined by incubating peptide (1 mM) and puri¢ed GRK5 (10 nM)
as previously described [18]. Reactions were applied to P-81 phospho-
cellulose paper, washed free of ATP and quantitated using scintilla-
tion counting.
2.4. Curve ¢tting and data analysis
Inhibition constants and curve ¢ts for data shown in Figs. 1 and 2
were obtained using GraphPad Prism (GraphPad Software, San Die-
go, CA, USA).
3. Results and discussion
We recently reported that actin binds and inhibits GRK5
[8]. We sought to determine if other known actin binding
proteins could relieve this inhibition. Surprisingly, addition
of K-actinin, rather than relieving actin-mediated inhibition
of GRK5, resulted in further GRK5 inhibition (data not
shown). Subsequent experiments demonstrated that K-actinin
alone inhibits GRK5-mediated casein phosphorylation (Fig.
Fig. 1. K-Actinin is a GRK-speci¢c inhibitor. Equivalent casein kinase activities of the four kinases (0.4^2.4 WM), GRK1, 2, 5 and PKA, were
incubated with casein and increasing concentrations of K-actinin in 60 WM [32P]Q-ATP (1 WCi), 20 mM Tris, pH 7.5, 10 mM MgCl2, 2 mM
EDTA and 1 mM DTT for 15 min at 30‡C as described in Section 2. The mean and S.E.M. of at least three experiments are plotted as percent
inhibition of casein phosphorylation, with 100% representing the phosphorylation observed in the absence of inhibitor. The IC50s for K-actinin
inhibition are 142 nM þ 35 for GRK1, 177 nM þ 134 for GRK2 and 139 nM þ 72 for GRK5.
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1, GRK5 panel). To determine if K-actinin inhibits other
GRKs as well, we incubated increasing concentrations of
chicken gizzard K-actinin with a GRK representative of
each of the GRK subfamilies. Data represented in Fig. 1
demonstrate that GRK1, GRK2 and GRK5 are all potently
inhibited by K-actinin. In contrast, casein phosphorylation by
PKA, another serine^threonine kinase, is not a¡ected. The
IC50 values for K-actinin inhibition of casein phosphorylation
by each GRK are identical (IC50s around 150 nM) and are
similar to the binding a⁄nities observed for other K-actinin
binding proteins, such as the NMDA receptor [19]. This sug-
gests that K-actinin, unlike calmodulin and actin, inhibits all
GRK subfamilies equally. Therefore, K-actinin probably binds
to a region that is conserved among all the GRKs but not
found in other kinases such as PKA.
K-Actinin and spectrin are closely related both by primary
sequence and actin binding activities (reviewed in [20]) leading
us to speculate that spectrin may also regulate GRK5 activity.
This prediction is borne out in the experiments illustrated in
Fig. 2 where GRK5-mediated rhodopsin phosphorylation is
measured in the presence of increasing concentrations of
K-actinin, spectrin and pro¢lin. Both K-actinin and spectrin
inhibit GRK5-mediated phosphorylation of the GPCR,
rhodopsin, while the unrelated actin binding protein, pro¢lin,
has no e¡ect (Fig. 2). K-Actinin and spectrin have similar IC50
values, indicating that these proteins are equally potent inhib-
itors of GRK5. The IC50 values for inhibition of soluble ca-
sein phosphorylation (Fig. 1) and membrane-bound rhodop-
sin phosphorylation (Fig. 2) by K-actinin are also identical
within experimental error, demonstrating that K-actinin di-
rectly inhibits GRK catalytic activity, rather than speci¢cally
interfering with the membrane association of these enzymes.
We chose GRK5 as the representative GRK to characterize
the e¡ects of calmodulin and PIP2 on K-actinin-mediated reg-
ulation. GRK5 has been extensively studied with regards to
calmodulin and PIP2 regulation and the binding sites on
GRK5 have been mapped [1,7]. Several groups have estab-
lished that calmodulin inhibits GRK5-mediated phosphory-
lation of membrane-bound receptor substrates (reviewed by
Pitcher et al. [1]). Pronin et al. demonstrated that calmodulin
interferes with the ability of GRK5 to recognize the receptor
substrate in a lipid environment [7]. To determine if calmod-
ulin has an e¡ect on K-actinin inhibition of GRK5, we as-
sayed GRK5-mediated phosphorylation of membrane-bound
and soluble substrates in the presence of K-actinin and 0.1 or
1.0 WM calcium-bound calmodulin. K-Actinin inhibition of
GRK5-mediated soluble substrate (casein) phosphorylation
is reversed by calmodulin in a dose-related way (Fig. 3, upper
panel). In contrast, addition of calmodulin along with K-acti-
nin further reduces L2AR phosphorylation in a dose-depen-
dent manner (Fig. 3, lower panel, compare columns 3 and 4
with column 2). This result agrees with previously reported
¢ndings that calmodulin inhibits GRK-mediated phosphory-
lation of other membrane-bound GPCRs [7]. Thus, calmodu-
lin binding to GRK5 provides a means of relieving K-actinin
inhibition to allow for soluble substrate phosphorylation
while simultaneously inhibiting membrane substrate phos-
phorylation.
We next examined the e¡ects of PIP2 on K-actinin-mediated
inhibition of GRK5 (Fig. 4). PIP2 binds to both K-actinin and
GRKs [1,21]. Unlike calmodulin which relieves K-actinin in-
hibition of soluble substrate phosphorylation, addition of
PIP2 (shaded columns) does not alter K-actinin inhibition of
GRK5-mediated soluble peptide phosphorylation (Fig. 4,
upper panel). Similar results were obtained using casein as a
soluble substrate (data not shown). To determine if PIP2
modulates K-actinin-mediated inhibition of L2AR, a prototyp-
ical GPCR, L2AR was reconstituted in the presence (Fig. 4,
lower panel, shaded columns) or absence (Fig. 4, lower panel,
unshaded columns) of 5% PIP2 and GRK5-mediated phos-
phorylation was quantitated. Addition of K-actinin to reac-
tions with L2AR reconstituted in vesicles without PIP2 (Fig. 4,
lower panel, unshaded columns), potently inhibits GRK5-
mediated L2AR phosphorylation. In contrast to what is ob-
Fig. 2. GRK5 inhibition is speci¢c to the spectrin family of actin
binding proteins. The indicated concentration of spectrin family
members, K-actinin (squares) and spectrin (triangles) or the unre-
lated actin binding protein, pro¢lin (circles), was added to GRK5
and bovine rod outer segments incubated for 5 min under light at
30‡C as described in Section 2. The mean and S.E.M. of at least
three independent experiments are shown. The IC50s for spectrin
family proteins are 258 nM þ 148 for K-actinin inhibition and
320 nM þ 123 for spectrin.
Fig. 3. Calmodulin relieves K-actinin inhibition of GRK5-mediated
casein phosphorylation, but not L2AR phosphorylation. Calmodulin,
either 0.1 WM (+) or 1.0 WM (++), was incubated with 1.8 WM K-ac-
tinin, 2 mM CaCl2 or 0.4 WM K-actinin, 2 mM CaCl2 and casein
(upper panel) or L2AR (3 pmol) reconstituted in 80% PC vesicles
(lower panel) and quanti¢ed as described in Section 2. Data are ex-
pressed as the percent of substrate phosphorylation in the absence
of K-actinin. The mean and S.E.M. of three independent experi-
ments are shown for bars 1, 3, 4 and 5. A representative experiment
is shown for bar 2.
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served with soluble substrates, addition of PIP2 to the L2AR
reconstitution vesicles relieved the inhibitory e¡ects of K-acti-
nin (Fig. 4, lower panel, shaded columns). Thus calmodulin
and PIP2 di¡erentially regulate K-actinin-mediated inhibition:
calmodulin speci¢cally relieves K-actinin-mediated inhibition
against soluble substrates while PIP2 exclusively relieves
K-actinin inhibition of membrane-bound substrates phos-
phorylation.
K-Actinin and spectrin contribute to the structural integrity
of cells by crosslinking actin ¢laments and binding lipids
which enables them to bridge membrane and cytoskeletal el-
ements to produce large multi-protein complexes [9]. GRKs
join a list of signal transducing proteins that bind K-actinin
and/or spectrin, including rabphilin 3A [22], PKN [23], PKC O
[24] and NMDA receptors [19,25].
Contrary to K-actinin and spectrin, calmodulin displaces
numerous signaling molecules, including GRK5 [7,8] from
binding to membranes and/or cytoskeletal proteins. One strik-
ing example is the NMDA receptor. Calcium-bound calmod-
ulin competes with K-actinin for binding to the NMDA re-
ceptor and is proposed to release the NMDA receptors from
K-actinin and cause a redistribution of receptors [19]. GRKs
could also be localized by an analogous mechanism whereby
K-actinin anchors and inhibits GRKs and calcium-bound cal-
modulin modulates this association.
Phosphatidylinositols also play an important role in the
regulation of K-actinin and its binding proteins. PIP2 levels
increase the actin crosslinking ability of K-actinin and co-lo-
calization of K-actinin and PIP2 has been demonstrated in
striated muscles cells [21]. Therefore, we propose that K-acti-
nin is involved in the cellular localization of GRKs and that
PIP2 and calmodulin regulate the K-actinin/GRK interaction
in vivo as follows: K-actinin inhibits GRKs under basal con-
ditions. GPCR agonist stimulation, which increases intracel-
lular PIP2 levels [26], would promote an interaction between
K-actinin and PIP2 that enables GRKs to phosphorylate
membrane-incorporated receptor substrates. Conversely,
when calcium-calmodulin levels increase, GRK5 is no longer
inhibited by K-actinin and does not interact with membranes,
but rather preferentially phosphorylates soluble substrates.
In addition to elucidating a mechanism whereby not only
GRK activity, but also GRK substrate speci¢city may be
regulated, these data demonstrate that K-actinin is a potent
inhibitor of all GRKs. No highly speci¢c inhibitors of GRKs
have been identi¢ed. Expression of a peptide which inhibits
GRK2/3 function in a genetic mouse model for human car-
diac failure rescues the mouse from heart failure, suggesting a
potential therapeutic role for inhibitors of GRK function [27].
Since K-actinin potently inhibits all GRKs, inhibitory peptides
derived from K-actinin represent a potential tool to directly
inhibit the activity of the GRK family. Since GPCRs are
involved in numerous human disease states and GRKs regu-
late GPCR function, development of a GRK inhibitor based
on the K-actinin sequence might have wide-ranging therapeu-
tic possibilities.
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